Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Rgenta Therapeutics
company
About
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.
- Cambridge,Massachusetts,United States
- 1 - 10
- https://www.rgentatx.com/
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $52M
- Industries
- Biotechnology,Health Care,Medical,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2018
- Number Of Employee
- 1 - 10
- Operating Status
- Active
- Legal Name
- Rgenta Therapeutics Inc.
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.It was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
5
$108.94M
Rgenta Therapeutics has raised a total of
$108.94M
in funding over 2 rounds. Their latest funding was raised on
Nov 29, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 29, 2022 | Series A | $52M | 10 |
AstraZeneca
CICC
|
— | Detail |
| Feb 7, 2022 | Series Unknown | $8.91M | — | — | — | Detail |
| May 25, 2021 | Seed | $18M | 3 | — | — | Detail |
| Apr 2, 2020 | Seed | $20M | 4 |
Boehringer Ingelheim Venture Fund
Matrix Partners China
|
— | Detail |
| Jan 21, 2020 | Series Unknown | $10.03M | — | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
4
10
Rgenta Therapeutics is funded by 10 investors.
AstraZeneca
and CICC
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
AstraZeneca
|
Yes | Series A |
|
CICC
|
Yes | Series A |
|
Boehringer Ingelheim Venture Fund
|
— | Series A |
Delos Capital
|
— | Series A |
Kaitai Capital
|
— | Series A |
|
|
— | Series A |
Legend Star
|
— | Series A |
Lilly Asia Ventures
|
— | Series A |
|
Matrix Partners China
|
— | Series A |
Vivo Capital
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
